Golidocitinib Combined With Selinexor for CAEBVD

Sponsor
Beijing Friendship Hospital
Study ID
NCT07369739
Phase
PHASE2/PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • CAEBV
  • EBV
  • Lymphohistiocytosis

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is a multicenter, prospective, single-arm clinical investigation, with patients with CAEBVD as the main research subjects, to evaluate the effectiveness of the combined treatment regimen of golidocitinib and selinexor.

Key Dates

Start date
Jan 1, 2026
Status verified
Jan 2026
Primary completion
Jan 1, 2027
Completion
Jan 1, 2028

Study Design

Enrollment
28 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental group:CAEBVD

Primary Outcome Measure

Disease Activity [ Time Frame: Weeks 8 after the start of treatment ]

Central Contacts

Related Studies